Crovalimab Biosimilar Monoclonal Antibody (Complement C5) for Research

Cat No.: GMP-Bios-ab-125

Pre-Made Crovalimab biosimilar, Whole mAb, Anti-C5/CO5 Antibody: Anti-CPAMD4/ECLZB therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.



Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-125-1mg 1mg 618

Size: 1mg | 10mg | 100mg



Product Details

Products Name (INN Index) Pre-Made Crovalimab biosimilar, Whole mAb, Anti-C5/CO5 Antibody: Anti-CPAMD4/ECLZB therapeutic antibody
INN Name Crovalimab
TargetCO5
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI Structure5b71:DC:BA
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2018
Year Recommended2019
CompaniesChugai Pharmaceutical;Roche
Conditions Approvedna
Conditions ActiveAtypical Haemolytic Uraemic Syndrome;Paroxysmal nocturnal haemoglobinuria
Conditions Discontinuedna
Development Techna



About target - C5

1. Protein Complement C5

2. Gene C5

3. Organism Homo sapiens (Human)

Function
Dipeptidase that hydrolyzes cystinyl-bis-glycine. Does not hydrolyze leukotriene D4 (LTD4) into leukotriene E4 (LTE4).

Catalytic activity
an L-aminoacyl-L-amino acid + H2O = 2 an L-α-amino acid
EC:3.4.13.19
Source: Rhea.

2 H2O + L-cystine-bis-glycine = 2 glycine + L-cystine
Source: Rhea.

Cofactor
Zn2+

Activity regulation
Inhibited by L-penicillamine.